Tim Davis
Angel Investor
Santa Monica, United States
Tim Davis is a Series A investor in Santa Monica focused on Health Care and Biotechnology. Timothy T Davis, MD is Board Certified in Physical Medicine and Rehabilitation (Physiatry) and Pain Medicine. The founder of Source Healthcare, Source Surgery Center, Alpha Diagnostics and he is an expert in spine and musculoskeletal disorders as well as interventional pain management to treat neck, back and sports injuries. Dr. Davis hasperformed extensive clinical research using biological therapies such as stem cells and other biologics for spine and joint injuries. He has consulted and invested in SaaS, medical device, biologics, cannabis, and psychedelics sectors.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Tim Davis invests in
Stages Tim Davis invests in
Countries Tim Davis invests in
Investment Focus
Industry
- Health Care 6 (60%)
- Biotechnology 4 (40%)
- Medical 3 (30%)
- Life Science 2 (20%)
- Pharmaceutical 2 (20%)
Stage
- Series A 5 (50%)
- Series B 2 (20%)
- Seed 1 (10%)
- Funding Round 1 (10%)
- Post-IPO Equity 1 (10%)
Country
- United States 3 (30%)
- United Kingdom 2 (20%)
- Germany 1 (10%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
MycoMedica Life Sciences, PBC
|
Psychedelic Medicines | Series A / Jul 30, 2021 | |
Beckley Psytech
|
Beckley Psytech operates as a psychedelic medicine company. The company is involved in exploring the therapeutic potential of psychedelic substances, such as psilocybin and other compounds, for mental health treatment. The company envisions the integration of clinically validated psychedelic medicines into contemporary medical practices to assistindividuals coping with depression and other significantly debilitating neuropsychiatric conditions characterized by a substantial unmet need. | Series B / May 01, 2021 | |
|
Beckley Psytech
|
Beckley Psytech operates as a psychedelic medicine company. The company is involved in exploring the therapeutic potential of psychedelic substances, such as psilocybin and other compounds, for mental health treatment. The company envisions the integration of clinically validated psychedelic medicines into contemporary medical practices to assistindividuals coping with depression and other significantly debilitating neuropsychiatric conditions characterized by a substantial unmet need. | Series A / Oct 31, 2020 | |
Bryn Pharma
|
Bryn Pharma is a pharmaceutical company that offers nasal-based epinephrine for anaphylaxis. Its bi-dose intranasal device is an alternative to epinephrine auto-injectors and is needle-free. It is easy to use and portable enabling patients to treat allergic reactions or anaphylactic reactions. | Series A / Feb 01, 2020 | |
Kulagy
|
In home physical therapy, covered by medicare or your insurance | Seed / Apr 01, 2019 | |
AtaiBeckley
|
ATAI is a global biotech company builder that leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering from mental health disorders. The company is committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in themental health space.ATAI Life Sciences was founded in 2018 and is based in Munich, Bayern, Germany. | $43M / Series B / Mar 01, 2019 | |
COMPASS Pathways
|
Compass Pathways is a mental health care company that focuses on developing therapies for treatment-resistant depression. The company is involved in researching and developing psilocybin therapy, a psychedelic compound found in certain mushrooms, as a potential treatment for depression.Compass Pathways conducts clinical trials and research toassess the safety and efficacy of psilocybin-assisted therapy in patients who have not responded to conventional depression treatments. The company's goal is to bring evidence-based innovation to mental health care and address the significant unmet need for effective and accessible treatments for depression. | $32.7M / Series A / Oct 03, 2018 | |
Definium Therapeutics
|
Definium Therapeutics provides psychedelic-inspired medicines and therapies for substance abuse disorders and other mental illnesses. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. | Post-IPO Equity / Aug 28, 2018 | |
Kiva Confections
|
Kiva Confections develops innovative ways for people to consume cannabis which nurture, enhance, and improve lives.By adhering to the highest standards of product quality, certified production methods, efficacy testing, and innovation, KIVA Confections will continue to produce and deliver a safe, convenient, and delicious tasting medical cannabisproducts to a discerning and deserving community.Kristi Knoblich and Scott Palmer established it in San Francisco, California in 2010. | Series A / Aug 01, 2018 | |
Forever Labs
|
Forever Labs collects and stores adult stem cells, and develops therapies based upon stem cell rejuvenation. | $2M / May 10, 2018 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Tim Davis invest in?
Tim Davis invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Tim Davis last invest?
The most recent investment recorded for Tim Davis closed in Jul 2021. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
